Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Evelyn Ellis-Grosse

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 5, 2005
The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial dataTimothy Babinchak, Evelyn Ellis-Grosse, Nathalie Dartois, et al.
Expert Opinion on Drug Discovery|March 15, 2013
Tigecycline: a case studyEvan Loh, Evelyn Ellis-Grosse, Peter J Petersen, et al.
International Journal of Surgery (London, England)|April 28, 2007
Tigecycline is efficacious in the treatment of complicated intra-abdominal infectionsPeter Fomin, Mircea Beuran, Audrius Gradauskas, et al.
Antimicrobial Agents and Chemotherapy|April 12, 2017
<i>In Vivo</i> Pharmacokinetics and Pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the Neutropenic Murine Thigh Infection Model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosaAlexander J Lepak, Miao Zhao, Brian VanScoy, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|August 16, 2005
Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trialSarvajna Sacchidanand, Robert L Penn, John M Embil, et al.
Diagnostic Microbiology and Infectious Disease|January 20, 2009
Application of patient population-derived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococciPaul G Ambrose, Alison K Meagher, Julie A Passarell, et al.
The Journal of Antimicrobial Chemotherapy|August 14, 2008
A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniaeKrasimir Vasilev, Galina Reshedko, Remus Orasan, et al.
Antimicrobial Agents and Chemotherapy|September 12, 2007
Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulationChristopher M Rubino, Lei Ma, Sujata M Bhavnani, et al.
Diagnostic Microbiology and Infectious Disease|December 17, 2008
Use of a clinically derived exposure-response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpointsPaul G Ambrose, Alison K Meagher, Julie A Passarell, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 5, 2005
The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial dataTimothy Babinchak, Evelyn Ellis-Grosse, Nathalie Dartois, et al.
Expert Opinion on Drug Discovery|March 15, 2013
Tigecycline: a case studyEvan Loh, Evelyn Ellis-Grosse, Peter J Petersen, et al.
International Journal of Surgery (London, England)|April 28, 2007
Tigecycline is efficacious in the treatment of complicated intra-abdominal infectionsPeter Fomin, Mircea Beuran, Audrius Gradauskas, et al.
Antimicrobial Agents and Chemotherapy|April 12, 2017
<i>In Vivo</i> Pharmacokinetics and Pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the Neutropenic Murine Thigh Infection Model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosaAlexander J Lepak, Miao Zhao, Brian VanScoy, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|August 16, 2005
Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trialSarvajna Sacchidanand, Robert L Penn, John M Embil, et al.
Diagnostic Microbiology and Infectious Disease|January 20, 2009
Application of patient population-derived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococciPaul G Ambrose, Alison K Meagher, Julie A Passarell, et al.
The Journal of Antimicrobial Chemotherapy|August 14, 2008
A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniaeKrasimir Vasilev, Galina Reshedko, Remus Orasan, et al.
Antimicrobial Agents and Chemotherapy|September 12, 2007
Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulationChristopher M Rubino, Lei Ma, Sujata M Bhavnani, et al.
Diagnostic Microbiology and Infectious Disease|December 17, 2008
Use of a clinically derived exposure-response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpointsPaul G Ambrose, Alison K Meagher, Julie A Passarell, et al.
Pageof 1